SignalXSignalX

ARDX ARDELYX, INC.

Q3 2025 10-Q
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
ARDELYX, INC. Overview

ARDELYX, INC. (ARDX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: XPHOZAH excluded from Medicare Part D as of January 1, 2025, shifting coverage to ESRD PPS, materially and negatively impacting revenue
  • • Updated financial risk: Accumulated deficit widened to $946.5 million as of September 30, 2025, increasing pressure on achieving sustained cash flow positivity
+3 more insights

Get deeper insights on ARDELYX, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.